(E)-1-[(1S)-1-(4-氟苯基)乙基]-3-[3-甲氧基-4-(4-甲基-1H-咪唑-1-YL)亚苄基]哌啶-2-酮
生物活性体外研究体内研究 用途与合成方法 MSDS (E)-1-[(1S)-1-(4-氟苯基)乙基]-3-[3-甲氧基-4-(4-甲基-1H-咪唑-1-YL)亚苄基]哌啶-2-酮价格(试剂级) 上下游产品信息
| 中文名称 | (E)-1-[(1S)-1-(4-氟苯基)乙基]-3-[3-甲氧基-4-(4-甲基-1H-咪唑-1-YL)亚苄基]哌啶-2-酮 |
|---|---|
| 中文同义词 | (E)-1-[(1S)-1-(4-氟苯基)乙基]-3-[3-甲氧基-4-(4-甲基-1H-咪唑-1-YL)亚苄基]哌啶-2-酮;(E)-1-[(1S)-1-(4-氟苯基)乙基]-3-[3-甲氧基-4-(4-甲基-1H-咪唑-1-基)亚苄基]哌啶-2-酮;化合物E 2012;(S,E)-1-(1-(4-氟苯基)乙基)-3-(3-甲氧基-4-(4-甲基-1H-咪唑-1-基)亚苄基)哌啶-2-酮;化合物E 2012,10 MM DMSO 溶液;E 2012,Γ-分泌酶调节剂;E 2012,γ-分泌酶调节剂 |
| 英文名称 | (E)-1-[(1S)-1-(4-Fluorophenyl)ethyl]-3-[3-methoxy-4-(4-methyl-1H-imidazol-1-yl)benzylidene]piperidin-2-one |
| 英文同义词 | (E)-1-[(1S)-1-(4-Fluorophenyl)ethyl]-3-[3-methoxy-4-(4-methyl-1H-imidazol-1-yl)benzylidene]piperidin-2-one;CS-510;E2012;E 2012;E-2012;(3E)-1-[(1S)-1-(4-Fluorophenyl)ethyl]-3-[[3-methoxy-4-(4-methyl-1H-imidazol-1-yl)phenyl]methylene]-2-piperidone;E-2012;E2012;2-Piperidinone, 1-[(1S)-1-(4-fluorophenyl)ethyl]-3-[[3-methoxy-4-(4-methyl-1H-imidazol-1-yl)phenyl]methylene]-, (3E)-;(S,E)-1-(1-(4-fluorophenyl)ethyl)-3-(3-methoxy-4-(4-methyl-1H-imidazol-1-yl)benzylidene)piperidin-2-one;1-[(1S)-1-(4-fluorophenyl)ethyl]-3-[[3-Methoxy-4-(4-Methyl-1H-iMidazol-1-yl)phenyl]Methylene]- |
| CAS号 | 870843-42-8 |
| 分子式 | C25H26FN3O2 |
| 分子量 | 419.49 |
| EINECS号 | |
| 相关类别 | API intermediates |
| Mol文件 | 870843-42-8.mol |
| 结构式 | ![(E)-1-[(1S)-1-(4-氟苯基)乙基]-3-[3-甲氧基-4-(4-甲基-1H-咪唑-1-YL)亚苄基]哌啶-2-酮 结构式](CAS/GIF/870843-42-8.gif) |
(E)-1-[(1S)-1-(4-氟苯基)乙基]-3-[3-甲氧基-4-(4-甲基-1H-咪唑-1-YL)亚苄基]哌啶-2-酮 性质
| 沸点 | 649.2±55.0 °C(Predicted) |
|---|---|
| 密度 | 1.19±0.1 g/cm3(Predicted) |
| 储存条件 | Store at -20°C |
| 溶解度 | DMF：10mg/mL；二甲基亚砜：10mg/mL； DMSO:PBS (pH 7.2) (1:3)：0.25mg/mL；乙醇：10mg/mL |
| 酸度系数(pKa) | 5.67±0.61(Predicted) |
| 形态 | 粉末 |
| 颜色 | 浅黄至黄色 |
| InChIKey | PUOAETJYKQITMO-LANLRWRYSA-N |
| SMILES | N1([C@H](C2=CC=C(F)C=C2)C)CCC/C(=C\C2=CC=C(N3C=NC(C)=C3)C(OC)=C2)/C1=O |
E 2012 是有效的 γ 分泌酶调节剂，不会影响 Notch 加工。E 2012 在胆固醇生物合成的最后一步抑制 3β-羟基固醇 Δ24-还原酶 (DHCR24)。E 2012 旨在通过减少淀粉样蛋白 β-42 减少阿兹海默氏病，并在大鼠多次重复给药后诱发白内障。
E2012 has concentration-dependent inhibitory effects on cholesterol biosynthesis in primary culture of rat hepatocytes and HepG2 cells with IC 50 s of 11.0, and 15.1 nM, respectively.
In vivo lenticular concentration of E 2012 after 13-week repeated dose with cataract was well above those where inhibition is observed in vitro. E 2012 induces cataract in the rat by inhibiting DHCR24 at the final step of cholesterol synthesis with associated elevation in desmosterol within the lens, preceded by desmosterol changes that would serve as a predictive safety biomarker for lenticular opacity.
安全信息
| 更新日期 | 产品编号 | 产品名称 | CAS号 | 包装 | 价格 |
|---|---|---|---|---|---|
| 2026/06/05 | HY-10016 | (E)-1-[(1S)-1-(4-氟苯基)乙基]-3-[3-甲氧基-4-(4-甲基-1H-咪唑-1-YL)亚苄基]哌啶-2-酮 E 2012 | 870843-42-8 | 1 mg | 310元 |
| 2026/06/05 | HY-10016 | (E)-1-[(1S)-1-(4-氟苯基)乙基]-3-[3-甲氧基-4-(4-甲基-1H-咪唑-1-YL)亚苄基]哌啶-2-酮 E 2012 | 870843-42-8 | 5mg | 980元 |